Tecentriq Approved for Metastatic Non-Squamous Non-Small Cell Lung Cancer

The FDA approved Roche’s Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer.

The approval was based on the results of a phase 3 multicenter study in which Tecentriq plus chemotherapy demonstrated significant overall survival and progression-free survival.

Roche currently has nine phase 3 Tecentriq trials underway for lung cancer, and multiple ongoing and planned trials for genitourinary, skin, breast, gastrointestinal, gynecological, and head and neck cancers.